Sarepta Therapeutics appointed former Tessera Therapeutics chief Michael Severino as CEO, effective July 28, 2026, after a turbulent period marked by gene therapy safety concerns, regulatory conflict and a stock decline of nearly 90% from early 2025. The leadership change
